Intra-Cellular Therapies Inc (NASDAQ:ITCI) SVP Robert E. Davis sold 899 shares of the company’s stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $13.53, for a total transaction of $12,163.47. Following the sale, the senior vice president now directly owns 31,155 shares of the company’s stock, valued at $421,527.15. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Intra-Cellular Therapies stock traded up $1.56 during mid-day trading on Friday, reaching $15.09. The company had a trading volume of 711,146 shares, compared to its average volume of 355,198. Intra-Cellular Therapies Inc has a 52 week low of $13.29 and a 52 week high of $25.82. The company has a market cap of $740.45 million, a PE ratio of -7.12 and a beta of 1.09.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. As a group, analysts forecast that Intra-Cellular Therapies Inc will post -3.03 earnings per share for the current year.
Institutional investors have recently modified their holdings of the business. Northern Trust Corp boosted its holdings in Intra-Cellular Therapies by 9.4% in the 2nd quarter. Northern Trust Corp now owns 540,016 shares of the biopharmaceutical company’s stock valued at $9,542,000 after purchasing an additional 46,453 shares during the period. BlackRock Inc. boosted its holdings in Intra-Cellular Therapies by 1.1% in the 2nd quarter. BlackRock Inc. now owns 3,794,986 shares of the biopharmaceutical company’s stock valued at $67,058,000 after purchasing an additional 41,856 shares during the period. Wasatch Advisors Inc. boosted its holdings in Intra-Cellular Therapies by 1.0% in the 3rd quarter. Wasatch Advisors Inc. now owns 1,928,018 shares of the biopharmaceutical company’s stock valued at $41,838,000 after purchasing an additional 19,787 shares during the period. NumerixS Investment Technologies Inc bought a new stake in Intra-Cellular Therapies in the 2nd quarter valued at $167,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in Intra-Cellular Therapies in the 2nd quarter valued at $1,756,000. 69.53% of the stock is owned by hedge funds and other institutional investors.
Several analysts recently issued reports on ITCI shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $32.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, November 7th. BidaskClub downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. Leerink Swann started coverage on shares of Intra-Cellular Therapies in a report on Tuesday, November 13th. They set an “outperform” rating and a $27.00 price objective for the company. ValuEngine downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Thursday, November 15th. Finally, Zacks Investment Research raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Tuesday, October 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Intra-Cellular Therapies has an average rating of “Buy” and an average price target of $28.25.
WARNING: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/12/08/insider-selling-intra-cellular-therapies-inc-itci-svp-sells-899-shares-of-stock.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.
Further Reading: What is a Call Option?
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.